Operating income before deduction of amortization: Passage Bio, Inc. (PASG)
Passage Bio, Inc. (PASG) develops gene therapies for rare CNS pathologies by correcting genetic defects in the brain. Patent protection and orphan drug status provide the company with a competitive market advantage. Absolute EBITDA confirms the financial dynamics, where this metric equals 0.00. Growth is expected from GM1 test results and FDA approval of an innovative gene delivery system.
Passage Bio - analytical breakdowns and key metrics (PASG)
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- business debt structure and liquidity details:
Debt to Capital Passage Bio, Inc.|PASG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Passage Bio Inc.|PASG - Company Aggregate Debts|Debt to Book Capitalization Ratio Passage Bio|PASG - Company Long-Term Debts|Short-Term Debt Volume Passage Bio|Immediate Liquidity passagebio.com
- business earnings and investment ratios data:
PASG - Net Income|Expected Net Income Passage Bio, Inc.|PASG - P/E Multiple|Market Cap to Projected Earnings Passage Bio Inc.|PASG - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Passage Bio|PASG - Operating profit EBITDA|Net earnings per share for the last 12 months Passage Bio|PASG - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months passagebio.com|PASG - Earnings per share growth in current year|Net earnings per share change forecast for next year Passage Bio, Inc.
Summary company analytics:Passage Bio, Inc. (PASG)
This metric measures the operational efficiency of the business by excluding the impact of depreciation and taxes, allowing for an assessment of the actual cash flow from core operations. By analyzing the EBITDA_Co metric, an investor can compare the capital intensity of developing unique DNA delivery methods to the brain with current returns, assessing the resilience of Passage Bio, Inc. (PASG) amidst the high risks of clinical trials.
Who Passage Bio, Inc. competes with
Operating income before deduction of amortization Biogen Idec (BIIB)|NBIX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization regencellbioscience.com RGC|AXSM: Operating profit EBITDA|ACADIA Pharma (ACAD) - Operating profit EBITDA|XENE (Xenon Pharmaceuticals Inc) - Operating profit EBITDA|VKTX - Operating profit before depreciation charges|Operating profit EBITDA SUPN|CPRX - Profit before interest, taxes and amortization|Denali Therapeutics Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization HRMY|Biohaven Pharmaceutical - Operating profit EBITDA|AMLX: Profit before payment of interest, taxes and amortization|TRVI: Operating profit EBITDA|PRAX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Anavex Life Sciences Corp.|Profit before interest, taxes and amortization CeriBell Inc CBLL|Operating profit before deduction of amortization PRTA (Prothena Corp)|ALEC (alector.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ANNX (Annexon, Inc.)|Operating income before deduction of amortization Omeros Corp (OMER)|NGNE - Profit before payment of interest, taxes and amortization|ACIU (AC Immune S.A.) - Operating profit before amortization|VYGR: Operating profit EBITDA|Operating profit before deduction of amortization Neumora Corp|Operating profit before deduction of amortization SCLX|tevogen.com (TVGN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Alpha Cognition (ACOG)|CGTX: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA IKT (Inhibikase)|Operating profit EBITDA Cassava Pharma SAVA|ASRT - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Coya Therapeutics, Inc. COYA|VTGN: Operating profit EBITDA|Operating profit before depreciation charges Ovid Therapeutics OVID|Profit before payment of interest, taxes and amortization Acumen Pharma|Operating profit before amortization CRVO (CervoMed Corporation)|Operating profit EBITDA ATHE|CLNN - Profit before interest, taxes and amortization|PepGen - Operating profit before deduction of amortization|Operating profit EBITDA Jupiter Neurosciences, Inc. JUNS|RLMD - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization ANVS (Annovis Bio Corporation)|gracetx.com (GRCE) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization fireflyneuro.com (AIFF)|Profit before payment of interest, taxes and amortization ANEW Medical|NeuroSense Therapeutics, Ltd. - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA RVPH|Operating profit EBITDA metaviatx.com (MTVA)|Profit before payment of interest, taxes and amortization NeurAxis, Inc. NRXS|Operating income before deduction of amortization Helius Medical Technologies, Inc. (HSDT)|NEUP - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Minerva Neurosciences Inc NERV|ATHA: Operating profit EBITDA|Addex (ADXN) - Operating profit EBITDA|ALZN (Alzamend Neuro Inc.) - Operating profit EBITDA|CYCN - Operating profit before depreciation charges|Operating profit EBITDA PTIX|KTTA - Profit before interest, taxes and amortization|Cortigent - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ATXI|Brainstorm Cell - Operating profit EBITDA|CARA: Profit before payment of interest, taxes and amortization|CHRO: Operating profit EBITDA|ELYM - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Intra-Cellular Therapies Inc.|Profit before interest, taxes and amortization Longboard LBPH|Operating profit before deduction of amortization MRNS (Marinus Pharmaceuticals)|NKGN (nkgenbiotech.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA NRBO (NeuroBo Pharmaceuticals, Inc.)|Operating income before deduction of amortization Sage Therapeutics Inc. (SAGE)|SNPX - Profit before payment of interest, taxes and amortization|TRVN (Trevena Inc) - Operating profit before amortization|VIGL: Operating profit EBITDA|Operating profit before deduction of amortization anewmeds.com|Operating profit before deduction of amortization CERE
